A review of the Oxford-AstraZeneca jab is about to commence after several European countries halted their rollouts.

The World Health Organization (WHO) with their Vaccine safety experts are meeting on Tuesday to commence the review.

After the vaccine was administered, there have been a number of cases and reports of blood clots in Europe.

This has given rise to this development even though the numbers are below the level one would expect in the general population.

At the moment, there are alternative reports concerning the blood clot which is evident in the claim of WHO that have said there is no evidence of a link.

Apart from the experts from WHO, the European Medicines Agency (EMA) – the European Union’s medicines regulator – is also meeting on Tuesday.

It is expected to issue its decision on the continued use of the Oxford-AstraZeneca vaccination on Thursday.

So far, about 17 million people in the EU and the UK have received a dose of the vaccine. But there are fewer than 40 cases of blood clots reported as of last week, AstraZeneca said.